FK 228

Pricing Availability   Qty
说明: Potent and selective class I histone deacetylase inhibitor; antitumor
别名: Depsipeptide,FR 901228,Romidepsin
化学名: Cyclo[(2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl], cyclic (3-5) disulfide
纯度: ≥98% (HPLC)
说明书
引用文献 (4)
评论
文献 (4)

生物活性 for FK 228

FK 228 is a potent and selective inhibitor of class I histone deacetylases (HDACs) (IC50 values are 36, 47, 510 and 14,000 nM for HDAC1, HDAC2, HDAC4 and HDAC6 respectively). Exhibits cytotoxicity against various human tumor cell lines; also exhibits antitumor activity against human tumor xenografts.

External Portal Information for FK 228

Chemicalprobes.org is a portal that offers independent guidance on the selection and/or application of small molecules for research. The use of Romidepsin is reviewed on the Chemical Probes website.

技术数据 for FK 228

分子量 540.7
公式 C24H36N4O6S2
储存 Store at -20°C
纯度 ≥98% (HPLC)
CAS Number 128517-07-7
PubChem ID 5352062
InChI Key OHRURASPPZQGQM-GCCNXGTGSA-N
Smiles O=C([C@H]([C@H](C)C)NC(/C(NC([C@@H]2NC([C@@H]([C@H](C)C)N1)=O)=O)=C/C)=O)O[C@H](/C=C/CCSSC2)CC1=O

上方提供的技术数据仅供参考。批次相关数据请参见分析证书。

Tocris products are intended for laboratory research use only, unless stated otherwise.

溶解性数据 for FK 228

溶剂 最高浓度 mg/mL 最高浓度 mM
溶解性
DMSO 5.41 10

制备储备液 for FK 228

以下数据基于产品分子量 540.7。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

选择批次从而根据批次分子量重新计算:
浓度/溶剂体积/质量 1 mg 5 mg 10 mg
0.1 mM 18.49 mL 92.47 mL 184.95 mL
0.5 mM 3.7 mL 18.49 mL 36.99 mL
1 mM 1.85 mL 9.25 mL 18.49 mL
5 mM 0.37 mL 1.85 mL 3.7 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

产品说明书 for FK 228

分析证书/产品说明书
选择另一批次:

参考文献 for FK 228

参考文献是支持产品生物活性的出版物。

Sasakawa et al (2003) Effects of FK228, a novel histone deacetylase inhibitor, on tumor growth and expression of p21 and c-myc genes in vivo. Cancer Lett. 195 161 PMID: 12767524

Matsubara et al (2009) Involvement of extracellular signal-regulated kinase activation in human osteosarcoma cell resistance to the histone deacetylase inhibitor FK228 [(1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-bis(propan-2-y J.Pharmacol.Exp.Ther. 328 839 PMID: 19073909

Furumai et al (2002) FK228 (depsipeptide) as a natural prodrug that inhibits class I histone deacetylases. Cancer Res. 62 4916 PMID: 12208741


If you know of a relevant reference for FK 228, please let us know.

按产品操作查看相关产品

查看全部 Class I HDAC Inhibitors

关键词: FK 228, FK 228 supplier, FK228, antitumour, antitumor, HDAC, histone, deacetylases, class, I, HDAC1, HDAC2, inhibitors, inhibits, anticancer, FR, 109228, FR109228, Depsipeptide, Romidepsin, 901228, Class, HDACs, 3515, Tocris Bioscience

4 篇 FK 228 的引用文献

引用文献是使用了 Tocris 产品的出版物。 FK 228 的部分引用包括:

Ting et al (2022) NF-κB-dependent repression of Sox18 transcription factor requires the epigenetic regulators histone deacetylases 1 and 2 in acute lung injury. Front Physiol 13 947537 PMID: 35991176

Steven L et al (2022) INF2-mediated actin filament reorganization confers intrinsic resilience to neuronal ischemic injury. Nat Commun 13 6037 PMID: 36229429

Fukuda et al (2015) Class I histone deacetylase inhibitors inhibit the retention of BRCA1 and 53BP1 at the site of DNA damage. J Pharmacol Exp Ther 106 1050 PMID: 26053117

Pozo et al (2018) Preclinical characterization of tyrosine kinase inhibitor-based targeted therapies for neuroendocrine thyroid cancer. Oncotarget 9 37662 PMID: 30701022


您是否知道使用了 Tocris FK 228 的优秀论文? 请告知我们.

FK 228 的评论

目前没有该产品的评论。 Be the first to review FK 228 and earn rewards!

Have you used FK 228?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

该领域的文献

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!

*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。


Epigenetics Scientific Review

Epigenetics Scientific Review

Written by Susanne Müller-Knapp and Peter J. Brown, this review gives an overview of the development of chemical probes for epigenetic targets, as well as the impact of these tool compounds being made available to the scientific community. In addition, their biological effects are also discussed. Epigenetic compounds available from Tocris are listed.

Cell Cycle & DNA Damage Repair Poster

Cell Cycle & DNA Damage Repair Poster

In normal cells, each stage of the cell cycle is tightly regulated, however in cancer cells many genes and proteins that are involved in the regulation of the cell cycle are mutated or over expressed. This poster summarizes the stages of the cell cycle and DNA repair. It also highlights strategies for enhancing replicative stress in cancer cells to force mitotic catastrophe and cell death.

Epigenetics in Cancer Poster

Epigenetics in Cancer Poster

This poster summarizes the main epigenetic targets in cancer. The dysregulation of epigenetic modifications has been shown to result in oncogenesis and cancer progression. Unlike genetic mutations, epigenetic alterations are considered to be reversible and thus make promising therapeutic targets.

Rheumatoid Arthritis Poster

Rheumatoid Arthritis Poster

Rheumatoid arthritis (RA) is a chronic destructive inflammatory autoimmune disease that results from a breakdown in immune tolerance, for reasons that are as yet unknown. This poster summarizes the pathology of RA and the inflammatory processes involved, as well as describing some of the epigenetic modifications associated with the disease and the potential for targeting these changes in the discovery of new treatments.